Sector News

Reeling from an FDA rejection, Telesta sheds 15% of its staff

March 9, 2016
Life sciences

Montreal biotech Telesta Therapeutics is cutting 15% of its payroll to conserve cash as the company works to get its once-rejected cancer drug back on track.

Most of the layoffs will affect Telesta’s manufacturing operation, management said, and the company is simultaneously slashing its expenditures. The biotech reported cash and equivalents totaling $20.3 million at the end of 2015.

Telesta, which trades on the Toronto exchange, is trying to pick up the pieces after the FDA rejected its application to win approval in bladder cancer last month. The company’s drug, MCNA, failed to satisfy regulators’ demands, and the FDA asked Telesta to conduct at least one more Phase III trial to establish the treatment’s efficacy and safety.

Now Telesta is requesting a so-called Type A meeting with the FDA, angling to sit down with agency staff to “obtain clarity” on what it needs to do to win approval, the company said in a statement.

“In parallel, we are working with our board of directors to review of all of our strategic options over the next few months,” CEO Michael Berendt said in a statement. “We are very aware that this review must be conducted and completed in a timely fashion to ensure that we conserve our key cash resources.”

Since MCNA’s rejection in early February, Telesta has been hinting that it may try to sell itself, with Berendt saying at the time that “the current climate of uncertainty in the financial markets has created opportunities for well-capitalized companies that were simply not available even a few months ago.”

Last year, Telesta flipped the European rights to MCNA to Ipsen, banking a $10 million upfront payment with a shot at $127 million more if the drug wins approval overseas.

By Damian Garde

Source: Fierce Biotech

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend